Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical has announced a board meeting scheduled for August 26, 2025, to review and approve the interim results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders’ perceptions and the company’s market positioning.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. It focuses on the development, manufacturing, and distribution of pharmaceutical products and medical devices, serving both domestic and international markets.
Average Trading Volume: 9,048,580
Technical Sentiment Signal: Hold
Current Market Cap: HK$72B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.